Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

114 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-13

Study Completion Date

2022-09-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

CT-100 is a platform that provides an interactive, software based therapeutic component that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital therapeutics (PDT/DTx), being developed by Click Therapeutics, Inc.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Depressed Mood Improvement Through Nicotine Dosing 2

NCT04433767

Depressive Disorder

COMPLETED PHASE2

Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application

NCT03678194

Depression Psychiatric Disorder Brain Diseases +2 more

RECRUITING NA

e-Mindfulness for Depression in Older Adults

NCT03922217

Depression Mental Health Disorder

COMPLETED NA

Non-invasive BCI and Application Verification for Depressed People

NCT06417437

Depression Major Depressive Disorder Bipolar Depression

RECRUITING PHASE4

Cognitive Training Video Game to Target Subclinical Depressive Symptoms in Youth

NCT05697627

Depression Subclinical Depressive Symptoms

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

CT-100 is a platform that provides an interactive, software based therapeutic component (CT-100-001) that may be used as part of a multimodal treatment in future prescription or non-prescription software-based digital therapeutics (PDT/DTx). CT-100-001 contains a class of Digital Neuro-activation and Modulation (DiNaMo) component. This DiNaMo component targets key neural systems (including, but not limited to, systems related to cognitive control, sensory-, perceptual-, affective-, pain-, attention-, social-, and self-processing) to optimally improve patients' cognitive and mental health. The CT-100-001 DiNaMo component is designed to improve cognitive impairments and mood challenges.

The purpose of the proposed basket study is to evaluate the initial effects of the CT-100-001, a DiNaMo component (the Study App) on cognitive functioning and related outcomes compared to Care-As-Usual across several non-DSM-5 indications. These indications have known high prevalence of cognitive impairments due to the illness and/or treatments. such as in Multiple Sclerosis, Breast or Lung Cancer, and Mild Cognitive Impairment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis Mild Cognitive Impairment Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Active Intervention Device vs. Care-as-Usual Control

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CT-100 DiNaMo (Study App) in Patients with Multiple Sclerosis

Randomized Controlled Study to Evaluate CT-100 DiNaMo (Study App) in Patients with Multiple Sclerosis

Group Type ACTIVE_COMPARATOR

CT-100 DiNaMo

Intervention Type OTHER

Active Treatment (Study App)

Care-as-Usual control in Patients with Multiple Sclerosis

Randomized controlled Study to Evaluate Care-as-Usual control in Patients with Multiple Sclerosis

Group Type SHAM_COMPARATOR

Care-as-Usual

Intervention Type OTHER

Care-As-Usual control

CT-100 DiNaMo (Study App) in Patients with Breast or Lung Cancer

Randomized Controlled Study to Evaluate CT-100 DiNaMo (Study App) in Patients with with Breast or Lung Cancer

Group Type ACTIVE_COMPARATOR

CT-100 DiNaMo

Intervention Type OTHER

Active Treatment (Study App)

Care-as-Usual control in Patients with Breast or Lung Cancer

Randomized Controlled Study to Evaluate Care-as-Usual control in Patients with with Breast or Lung Cancer

Group Type SHAM_COMPARATOR

Care-as-Usual

Intervention Type OTHER

Care-As-Usual control

CT-100 DiNaMo (Study App) in Patients with Mild Cognitive Impairment

Randomized Controlled Study to Evaluate CT-100 DiNaMo (Study App) in Patients with Mild Cognitive Impairment

Group Type ACTIVE_COMPARATOR

CT-100 DiNaMo

Intervention Type OTHER

Active Treatment (Study App)

Care-as-Usual in Patients with Mild Cognitive Impairment

Randomized Controlled Study to Evaluate Care-as-Usual in Patients with Mild Cognitive Impairment

Group Type SHAM_COMPARATOR

Care-as-Usual

Intervention Type OTHER

Care-As-Usual control

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CT-100 DiNaMo

Active Treatment (Study App)

Intervention Type OTHER

Care-as-Usual

Care-As-Usual control

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

A participant will be eligible for entry into the study if all the following criteria are met:

1. Age ranges in years: 22-52 for Multiple Sclerosis, 35-65 for Cancer (Breast or Lung), and 45-75 for Mild Cognitive Impairment.
2. Diagnosis of indication under study (Multiple Sclerosis, Cancer - Breast or Lung, Mild Cognitive Impairment)
3. Self-reported cognitive impairment and mood symptoms that began in the context of the primary indication under study.
4. Fluent in written and spoken English (confirmed by ability to read and comprehend the informed consent form.)
5. Willing and able to comply with study protocol and assessments, evidenced by completion of the Screening Survey.
6. Lives in the United States.
7. Has an active email address and is willing and able to receive email messages.
8. Is the sole user of an iPhone or a smartphone with an Android operating system, and with cellular and/or internet access for the duration of the study period.

Exclusion Criteria

A participant is excluded from the study if any of the following criteria apply:

1. Physician-diagnosed insomnia in the Screening Survey.
2. Cognitive impairment/mood symptoms or clinical diagnosis of depression attributed to a condition other than the underlying medical condition.
3. Is currently pregnant or breastfeeding.
4. Substance use disorder within the past 1 year.
5. Initiation or change in central nervous system-active medication (e.g., antidepressants) during the last 2 months.
6. Participation in a clinical trial within the last 3 months.
7. Anticipates a lifestyle change or change in current treatment during the study period that could affect cognitive functioning.
8. Visual, dexterity or cognitive deficit so severe that precludes the use of an app.
9. Severe neurological disorders impairing brain function.
10. Psychiatric hospitalization in the past 6 months.

Minimum Eligible Age

22 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No